Second Cures Draft Leaves Out Exclusivity, But Has Placeholder For Dormant Therapies

The second draft of the House Energy and Commerce Committee's 21st Century Cures legislation includes no mention of increased exclusivity for a variety of new drugs, including the 15 years for dormant therapies included in an earlier draft that along with other exclusivity proposals had been protested by the generic drug lobby and other stakeholders like state Medicaid directors. However, sources say provisions to incentivize development of dormant therapies, pushed by the National Health Council and a bevy of patients...